ATE476992T1 - Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper - Google Patents

Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper

Info

Publication number
ATE476992T1
ATE476992T1 AT04800068T AT04800068T ATE476992T1 AT E476992 T1 ATE476992 T1 AT E476992T1 AT 04800068 T AT04800068 T AT 04800068T AT 04800068 T AT04800068 T AT 04800068T AT E476992 T1 ATE476992 T1 AT E476992T1
Authority
AT
Austria
Prior art keywords
hgf
neutralizing antibodies
antibodies binding
neutralizable epitope
binding
Prior art date
Application number
AT04800068T
Other languages
English (en)
Inventor
Junho Chung
Youngmi Hur
Original Assignee
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct filed Critical Nat Cancer Ct
Application granted granted Critical
Publication of ATE476992T1 publication Critical patent/ATE476992T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04800068T 2003-11-11 2004-11-09 Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper ATE476992T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030079482A KR100556660B1 (ko) 2003-11-11 2003-11-11 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
PCT/KR2004/002888 WO2005044848A1 (en) 2003-11-11 2004-11-09 Neutralizable epitope of hgf and neutralizing antibody binding to the same

Publications (1)

Publication Number Publication Date
ATE476992T1 true ATE476992T1 (de) 2010-08-15

Family

ID=36660022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04800068T ATE476992T1 (de) 2003-11-11 2004-11-09 Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper

Country Status (10)

Country Link
US (2) US7408043B2 (de)
EP (1) EP1694700B1 (de)
JP (1) JP4446393B2 (de)
KR (1) KR100556660B1 (de)
CN (2) CN101434654A (de)
AT (1) ATE476992T1 (de)
AU (1) AU2004287743B2 (de)
DE (1) DE602004028651D1 (de)
ES (1) ES2346887T3 (de)
WO (1) WO2005044848A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
AR061400A1 (es) 2005-10-14 2008-08-27 Chugai Kabushiki Kaisha Agentes para suprimir el dano a los islotes transplantados despues del transplante de islotes
JP5191235B2 (ja) 2005-10-21 2013-05-08 中外製薬株式会社 心疾患治療剤
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
KR20080084818A (ko) * 2005-11-25 2008-09-19 각고호우징 게이오기주크 전립선암 치료제
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
EP2380908A1 (de) 2006-06-02 2011-10-26 Aveo Pharmaceuticals, Inc. Hepatozytenwachstumsfaktor (hgf)-bindende proteine
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
BRPI0806812B8 (pt) 2007-01-23 2021-09-14 Chugai Pharmaceutical Co Ltd Agente para suprimir reação de rejeição crônica e uso de um inibidor de il-6
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
MX2009013886A (es) * 2007-06-25 2010-01-27 Amgen Inc Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
CN104906581A (zh) 2008-06-05 2015-09-16 国立研究开发法人国立癌症研究中心 神经浸润抑制剂
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
JP6055312B2 (ja) 2010-03-10 2017-01-11 ゲンマブ エー／エス Ｃ−ｍｅｔに対するモノクローナル抗体
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
EP2402370A1 (de) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Neuartiger Antikörper zur Diagnose und/oder Prognose von Krebs
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
EP2635602B1 (de) * 2010-11-03 2016-09-07 Argen-X Nv Anti-c-met-antikörper
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
KR102119223B1 (ko) 2012-03-15 2020-06-05 서울대학교산학협력단 그렘린-1에 대한 항체
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9062104B2 (en) * 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
BR112016006502A2 (pt) 2013-09-30 2017-09-19 Chugai Pharmaceutical Co Ltd Método para a produção de molécula de ligação de antígeno usando-se fago auxiliar modificado
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2016060297A1 (ko) * 2014-10-16 2016-04-21 주식회사 파멥신 VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
EP3698808B1 (de) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 rezeptorantikörper enthaltende medizinische zusammensetzung zur verhinderung von postoperativer adhäsion
TW202321313A (zh) * 2021-09-13 2023-06-01 德州大學系統董事會 Ｔｒｅｍ２抗原結合蛋白及其用途
WO2023056527A1 (en) * 2021-10-07 2023-04-13 The University Of Queensland Proteinaceous molecules and uses therefor
KR20230148433A (ko) * 2022-04-14 2023-10-25 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 중화항체의 조합 요법
KR102789265B1 (ko) * 2022-04-14 2025-04-02 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 결합 억제 물질의 조합 요법
KR20250058158A (ko) 2023-10-20 2025-04-30 주식회사 셀랩메드 암 치료용 약제학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241574A (zh) * 1998-07-02 2000-01-19 中国人民解放军第四军医大学 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体

Also Published As

Publication number Publication date
CN100447158C (zh) 2008-12-31
US7408043B2 (en) 2008-08-05
EP1694700A4 (de) 2007-10-31
JP4446393B2 (ja) 2010-04-07
US20070036789A1 (en) 2007-02-15
WO2005044848A1 (en) 2005-05-19
EP1694700A1 (de) 2006-08-30
KR20050045419A (ko) 2005-05-17
HK1098769A1 (zh) 2007-07-27
EP1694700B1 (de) 2010-08-11
JP2007532097A (ja) 2007-11-15
ES2346887T3 (es) 2010-10-21
US20090023894A1 (en) 2009-01-22
AU2004287743B2 (en) 2008-10-09
CN101434654A (zh) 2009-05-20
DE602004028651D1 (de) 2010-09-23
CN1878790A (zh) 2006-12-13
KR100556660B1 (ko) 2006-03-10
AU2004287743A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
NO2017032I1 (no) bezlotoksumab
WO2019178269A3 (en) Antibodies that bind cd39 and uses thereof
PA8645301A1 (es) Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
NZ597767A (en) Antibodies to IL-6 and use thereof
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
JOP20190292A1 (ar) استخدام الأجسام المضادة لربط il-1? في علاج السرطان
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
ECSP20025198A (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos
SG166090A1 (en) Il-13 binding agents
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
NZ594682A (en) Fully human antibodies specific to cadm1
DE602004027992D1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
BR112022023117A2 (pt) Constructos de anticorpos de domínio único neutralizantes de sars-cov2
IL177825A0 (en) Natural igm antibodies and inhibitors thereof
ATE552266T1 (de) Modifizierte hiv-1-hüllproteine
DE50300486D1 (de) Chromatreduziertes hydraulisches Bindemittel
TR201900355T4 (tr) Anti-ctla-4 antikor kompozisyonları.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1694700

Country of ref document: EP